PHARMA M&A WAVE SET TO REACH INDIA

While merger-mania is gripping the global pharma industry, a similar trend may soon spill over to the Indian market, with pharma companies quoting at low valuations and saddled with huge debt.

Recently, there have been a spate of deals in the pharma space led by Pfizer Inc's acquisition of Wyeth for $68 billion, followed by the merger of Merck and Schering Plough. Experts believe that Bristol-Myers Squibb may be the next target of an acquisition, and many more deals are inevitable. Back home, there has been speculation about Wockhardt and Piramal Healthcare being potential acquisition targets.

The Times Of India

Biotech industry revenue doubles to $2 bn in a year

The biotech industry is going great guns. The industry’s revenue revenue hit the $2-billion mark during 2006-07, up from $1 billion in 2004-05. The industry is now aiming to garner revenue of $5 billion before 2010. This sterling performance has its roots abroad. According to industry players, escalating research and development expenses and stringent policies are making manufacturers from the regulated Markets look towards India for cutting costs.

The Financial Express
http://www.financialexpress.com/news/
Biotech-industry-revenue-doubles-to-2-bn-in-a-year/256621/